Axsome Therapeutics (AXSM) | Stock Overview & Key Data
Axsome Therapeutics Performance Comparison
Stock Range
Today's Range
52 Week Range
All-Time High: $257.94 on June 12, 2026
Explore how other US stocks compare to their 52-week ranges: View US Market 52-Week Insights
Key Statistics
Join Our United States Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
Financial Highlights
Quarter Income Flow
Dec 31, 2025
Annual Income Flow
2025
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Axsome Therapeutics
AXSM
|
9.51B Mid-cap | 7.77% | 11.28% | 60.15% | 73.28% | 41.81% | 145.12% | 200.20% | 278.87% | 3,924.76% | 2,713.34% | 2,713.34% |
|
Vertex
VRTX
|
109.45B Large-cap | 1.69% | 3.09% | -3.36% | -1.15% | -0.37% | -2.31% | 27.89% | 136.85% | 413.01% | 888.51% | 1,245.83% |
|
Regeneron
REGN
|
80.98B Large-cap | 0.60% | -11.93% | -18.75% | -18.29% | -20.78% | 15.66% | -21.83% | 13.80% | 72.82% | 1,033.17% | 4,804.97% |
|
Praxis Precision
PRAX
|
9.60B Mid-cap | 4.46% | -22.78% | -13.27% | -4.29% | -7.63% | 501.76% | 1,560.93% | -17.42% | -36.07% | -36.07% | -36.07% |
|
Bio-Techne
TECH
|
9.07B Mid-cap | 6.69% | 29.72% | 15.08% | -4.29% | -5.83% | 6.89% | -31.20% | -49.99% | 96.15% | 179.21% | 318.28% |
|
Vaxcyte
PCVX
|
8.82B Mid-cap | 6.97% | -5.40% | -10.90% | 11.77% | 6.67% | 37.33% | -7.21% | 120.95% | 81.49% | 81.49% | 81.49% |
Ownership & Short Interest
Calculate Your Axsome Therapeutics Investment Returns
Long-Term Investment Performance Analysis
Axsome Therapeutics stock price in Jul 2016 was $7.76, A $1,000.00 lump sum investment in Axsome Therapeutics made 9 years ago would be worth approximately $32,654.64 today, representing a exceptional return of 3,165.46%. This translates to an annualized return (CAGR) of 42.17%.
9 Years 10 Months Investment Scenario (Jul 2016 - Jun 2026)
Investment Breakdown
Value Comparison
Disclaimer: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing. Past performance does not guarantee future results.
Frequently Asked Questions
- What is AXSM's 52-week high and low?
- In the last 52 weeks, Axsome Therapeutics reached a high of $257.92 (on June 12, 2026) and a low of $96.09 (on August 4, 2025).
- What is the market cap and P/E ratio for AXSM?
- Curious about Axsome Therapeutics's size and valuation? Its market capitalization stands at 9.51B. When it comes to valuation, the P/E ratio (trailing twelve months) is -50.54, and the forward P/E (looking ahead) is 29.85.
- Does AXSM pay dividends? If so, what's the yield?
- As for dividends, Axsome Therapeutics isn't currently offering a significant yield, or that specific data isn't available right now.
- Who are Axsome Therapeutics's main competitors or similar companies to consider before investing?
When looking at Axsome Therapeutics, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Vertex
VRTX109.45B Healthcare Biotechnology -2.31% 27.89% Regeneron
REGN80.98B Healthcare Biotechnology 15.66% -21.83% Praxis Precision
PRAX9.60B Healthcare Biotechnology 501.76% 1,560.93% Bio-Techne
TECH9.07B Healthcare Biotechnology 6.89% -31.20% Vaxcyte
PCVX8.82B Healthcare Biotechnology 37.33% -7.21% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Axsome Therapeutics Inc.? (e.g., ROE, Debt/Equity)
- To get a sense of Axsome Therapeutics's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is -252.12%, the Debt to Equity ratio from the most recent quarter is 247.03, and its Gross Profit Margin stands at 93.71%.
- What is the recent revenue and earnings growth for AXSM?
- Looking at Axsome Therapeutics's growth, its revenue over the trailing twelve months (TTM) was $638M. Compared to the same quarter last year (YoY), quarterly revenue grew by 65.00%, and quarterly earnings saw a YoY growth of 65.03%.
- How much of AXSM stock is held by insiders and institutions?
- Wondering who owns Axsome Therapeutics stock? Company insiders (like executives and directors) hold about 15.47% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 76.52%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.